Literature DB >> 12230878

Flavonoid antioxidant silymarin and skin cancer.

Rana P Singh1, Rajesh Agarwal.   

Abstract

Oxidative stress is one of the key players in skin carcinogenesis, and therefore identifying nontoxic strong antioxidants to prevent skin cancer is an important area of research. In both animal and cell culture studies, we have shown that silymarin, a naturally occurring polyphenolic flavonoid antioxidant, exhibits preventive and anticancer effects against skin cancer. For example, silymarin strongly prevents both photocarcinogenesis and skin tumor promotion in mice, in part, by scavenging free radicals and reactive oxygen species and strengthening the antioxidant system. We also found that this effect of silymarin is by inhibiting endogenous tumor promoter tumor necrosis factor alpha in mouse skin, a central mediator in skin tumor promotion. In mechanistic studies, silymarin inhibits mitogenic and cell survival signaling and induces apoptosis. Furthermore, silymarin effectively modulates cell-cycle regulators and check points toward inhibition of proliferation, and growth arrest in G0-G1 and G2-M phases of the cell cycle. Thus, due to its mechanism-based chemopreventive and anticancer effects in experimental models, silymarin is an important candidate for the prevention and/or therapy of skin cancer, as well as other cancers of epithelial origin in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12230878     DOI: 10.1089/15230860260220166

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  18 in total

Review 1.  Phytochemicals for the Prevention of Photocarcinogenesis.

Authors:  Mary K Montes de Oca; Ross L Pearlman; Sarah F McClees; Rebecca Strickland; Farrukh Afaq
Journal:  Photochem Photobiol       Date:  2017-03-14       Impact factor: 3.421

2.  Process optimization and photostability of silymarin nanostructured lipid carriers: effect on UV-irradiated rat skin and SK-MEL 2 cell line.

Authors:  Pooja Singh; Mahendra Singh; Jovita Kanoujia; Malti Arya; Shailendra K Saraf; Shubhini A Saraf
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

3.  The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.

Authors:  Rashid Elhag; Elizabeth A Mazzio; Karam F A Soliman
Journal:  Anticancer Res       Date:  2015-03       Impact factor: 2.480

4.  Identification of urushiols as the major active principle of the Siddha herbal medicine Semecarpus Lehyam: Anti-tumor agents for the treatment of breast cancer.

Authors:  Weimin Zhao; Lili Zhu; Sowmyalakshmi Srinivasan; Chendil Damodaran; Jürgen Rohr
Journal:  Pharm Biol       Date:  2009-09-01       Impact factor: 3.503

Review 5.  Phytochemicals for the Management of Melanoma.

Authors:  Harish Chandra Pal; Katherine Marchiony Hunt; Ariana Diamond; Craig A Elmets; Farrukh Afaq
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

6.  Enhanced bioavailability and hepatoprotective effect of silymarin by preparing silymarin-loaded solid dispersion formulation using freeze-drying method.

Authors:  Dong Yu Lim; Minyeong Pang; Jaehyeok Lee; Jihoon Lee; Ji-Hyeon Jeon; Jin-Hyang Park; Min-Koo Choi; Im-Sook Song
Journal:  Arch Pharm Res       Date:  2022-09-30       Impact factor: 6.010

Review 7.  Cosmeceuticals and silibinin.

Authors:  Rana P Singh; Rajesh Agarwal
Journal:  Clin Dermatol       Date:  2009 Sep-Oct       Impact factor: 3.541

8.  Topical delivery of silymarin constituents via the skin route.

Authors:  Chi-feng Hung; Yin-ku Lin; Li-wen Zhang; Ching-hsien Chang; Jia-you Fang
Journal:  Acta Pharmacol Sin       Date:  2009-12-21       Impact factor: 7.169

9.  The treatment of melasma by silymarin cream.

Authors:  Tagreed Altaei
Journal:  BMC Dermatol       Date:  2012-10-02

10.  Identification of a potent herbal molecule for the treatment of breast cancer.

Authors:  Srinivas Koduru; Srinivasan Sowmyalakshmi; Raj Kumar; Rohini Gomathinayagam; Jürgen Rohr; Chendil Damodaran
Journal:  BMC Cancer       Date:  2009-01-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.